Network Version
KML29 Data Sheet
| Product Name: | KML29 |
 |
|---|---|---|
| CAS No.: | 1380424-42-9 | |
| Cat. No.: | HY-18977 | |
| MWt: | 549.42 | |
| Formula: | C24H21F6NO7 | |
| Purity : | >98% | |
| Solubility: | DMSO : 50 mg/mL (91.01 mM; Need ultrasonic) | |
| Mechanisms: | Target: Inflammation/Immunology Metabolic Disease | |
| Biological Activity: | ||
|
KML29 is an extremely selective, orally active and irreversible MAGL inhibitor, with IC50 values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH[1][2].
IC50 & Target: IC50: 15 nM (mouse MAGL), 43 nM (rat MAGL), 5.9 nM (human MAGL)[2].
In Vitro: KML29 dose-dependently elevates brain 2-AG level up to 10-fold without alteration in brain levels of anandamide, palmitoylethanolamide, and oleoylethanolamide[2]. KML29 is a potent inhibitor of 2-AG hydrolysis, but did not affect AEA hydrolysis at any concentration tested[2]. In Vivo: KML29 enhibits antinociceptive activity without cannabimimetic side effects[3]. KML29 (20 mg/kg) has a significant but modest protective effect against LPS-induced fever[3]. |
||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com